Navigation Links
Genaera Presents Preliminary Phase 1b Data for Trodusquemine (MSI-1436)
Date:2/10/2009

-Cohort 1 Data Promising for Type 2 Diabetes-

PLYMOUTH MEETING, Pa., Feb. 10 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today reported promising preliminary Phase 1b clinical data for trodusquemine (MSI-1436), the first-in-class, highly selective inhibitor of PTP1B and Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity. Mr. Jack Armstrong, President and CEO of Genaera, presented data from the first of three cohorts in an ascending multiple dose study of MSI-1436 (Study 102), during the BIO CEO & Investor Conference in New York.

Data from cohort 1, in which eight doses of 3 mg/m2 of MSI-1436 were administered over 21 days to overweight and obese type 2 diabetic subjects, demonstrated meaningful improvement in four primary outcomes used to evaluate type 2 diabetes, including:

  • A 9.5% decrease in fasting blood glucose with a resulting 17% differential compared to placebo subjects in the same cohort;
  • A 7% decrease in the area under the curve during the oral glucose tolerance test;
  • An 11.3% decrease in serum fructosamine, which is used to monitor short-term (2-3 weeks) blood sugar control; and
  • A 0.4% decrease in hemoglobin A1C (HbA1C), used to monitor longer-term (2-3 months) blood sugar control.

"It is very exciting to see a believable biologic response to MSI-1436 in cohort 1 of Study 102. While 3 mg/m2 of drug was thought to be a sub-therapeutic dose, the data has demonstrated otherwise. We are currently completing the in-house portion of the second cohort of this study evaluating 6 mg/m2 of MSI-1436 and the initial results support proceeding to the 10 mg/m2 cohort which will begin later this month. Final Study 102 data is expected in the second quarter," comme
'/>"/>

SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Genaera Presents Promising Preclinical Data for Trodusquemine (MSI-1436) at Keystone Symposia
2. Genaera Begins Phase 1b Trial of Trodusquemine (MSI-1436) in Overweight and Obese Type 2 Diabetics
3. Genaera Corporation Reports Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
4. Genaera Releases Phase 1 Data and New Preclinical Data on the CNS Function of Trodusquemine (MSI-1436) at CBI Obesity Summit
5. Genaera Corporation Presents Data on Mechanism of Inhibition of PTP-1B for Trodusquemine (MSI-1436) at Federation of American Societies for Experimental Biology (FASEB) Meeting
6. Genaera Corporation Presents Additional Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at American Diabetes Association
7. Genaera Corporation Announces MSI-1436 Data Presented at Society of Neuroscience Meeting
8. Genaera Announces MedImmune Initiation of Phase 2a Trial of Antibody Targeting Interleukin-9 in Patients with Asthma
9. Genaera Corporation Presents Promising Preclinical Type 2 Diabetes Data for Trodusquemine (MSI-1436) at Keystone Symposia
10. Genaera Announces Diabetes IND In Effect for Trodusquemine (MSI-1436)
11. Genaera Begins Dosing Second Phase 1 Trial of Type 2 Diabetes and Obesity Compound Trodusquemine (MSI-1436)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/27/2014)... , Aug. 27, 2014 Reportbuyer.com ... Collaborative R&D Terms & Agreements ... https://www.reportbuyer.com/product/2276220/Collaborative-RD-Terms--Agreements-in-Pharma-Biotech-and-Diagnostics.html The Collaborative R&D ... Diagnostics report provides comprehensive understanding and unprecedented ... agreements entered into by the worlds leading ...
(Date:8/27/2014)... FAIRFAX, Va. , Aug. 27, 2014 ... in the legs due to buildup of fatty plaque ... expected in the aging patient population and in incidences ... Radiology offers its Lower Extremity Arterial RevascularizatioN ... Ariz. Endovascular specialists and interested residents and ...
(Date:8/27/2014)...  Decision Resources Group finds that physicians surveyed ... gastroenterology, endocrinology and nephrology) expect the robustness and ... been assessed in to be the strongest influencers ... Other key findings from the ... of Biosimilars Across Physician Specialties : ...
Breaking Medicine Technology:Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 2Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 3Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 4Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 5Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 6Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 7Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 8Collaborative R&D Terms & Agreements in Pharma, Biotech and Diagnostics 9LEARN to Treat Peripheral Arterial Disease Patients 2LEARN to Treat Peripheral Arterial Disease Patients 3Surveyed Physicians Expect to Choose Between Future Biosimilars Based on Robustness and Number of Clinical Trials 2
... CT Colonography Trial Raise Questions for,Patients, OAK ... CT Colonography Trial, published in the September 18 ... improvements in the technology,s,ability to diagnose intermediate- to ... testing is not as effective in diagnosing small ...
... September 18th New England Journal of,Medicine, Each year ... these deaths could be prevented by regular screening. Yet, ... be screened for the disease are,not being tested - ... with current screening exams., However, results of an ...
Cached Medicine Technology:ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 2ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 3ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 4ASGE Encourages Patients to Speak to Their Doctor About Colorectal Cancer Screening Options 5MultiVu Video Feed: Major Trial Demonstrates Comparable Accuracy of Virtual Colonoscopy and Standard Colonoscopy 2
(Date:8/27/2014)... 28, 2014 Spine Guide has built ... of information on spinal health. Now, the e-health site ... people suffering from back pain symptoms. Spine Guide specializes ... surgery, and lumbar spine surgery. , Some of the ... or stabbing pain, pain radiating down the leg, inability ...
(Date:8/27/2014)... The National League for Nursing is pleased to ... became the inaugural director of the NLN/Chamberlain College ... of Nursing Education , effective August 11. The center ... for Transformative Excellence, established with the League’s historic move ... Under Dr. Dennis’s leadership, the NLN/Chamberlain Center will expand ...
(Date:8/27/2014)... Recently, Skmen.com, a renowned garment manufacturer ... celebrity bodycon dresses . The company has rich experience ... trendy items in stock and ready to ship: celebrity ... sleeve sweater dresses and so forth. All of them ... , “We are proud to announce the new collection ...
(Date:8/27/2014)... Philadelphia, PA. Inc. magazine ranked ... 500 list, an exclusive ranking of the nation’s fastest-growing ... look at the most important segment of the economy ... early exposure as members of the Inc. 500 list ... , “Some of world’s greatest companies have had their ...
(Date:8/27/2014)... 2014 All Canada Goose Parkas ... go from classic to modern. With unique detailing such as ... them is a step up in opulence. Recently, the company ... Parkas for 2014. , True enough, the new ... great discounts (up to 28% off) on all these brand ...
Breaking Medicine News(10 mins):Health News:Spine Guide Offering New Overview of Surgical Options For Back Pain 2Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 2Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 3Health News:Betty Pierce Dennis to Lead NLN/Chamberlain College of Nursing Center for the Advancement of the Science of Nursing Education 4Health News:Skmen.com Unveils Its New Celebrity Bodycon Dresses for Its Loyal Customers 2Health News:Inc Magazine Unveils 33rd Annual List of America's Fastest-Growing Private Companies - the Inc. 500 2Health News:CanadaGooseJackor.nu: 2014 Canada Goose Banff Parkas At Discounted Prices 2
... Anti-fungal and anti-bacterial additives in house paint are present ... the city of Lausanne, says a study to be ... Union (AGU) conference in San Francisco. Chemicals engineered to ... in order to prevent molding and plant growth. Washed ...
... By Alan Mozes HealthDay Reporter , FRIDAY, Dec. ... is just one more form of entertainment. But for Katie ... true cause for celebration. "It was absolute redemption," said ... Michael, 16-year-old son Dylan, and 14-year-old son Dusty -- who ...
... GREENVILLE, S.C. From their fourth-floor state-of-the-art laboratory in ... University bioengineering scientists and students help keep the feet ... new facility, which opens this week, houses one of ... hip, knee and other artificial joints that were removed ...
... certain form of inherited hearing loss have increased ... study by Professor Thomas Jentsch of the Leibniz-Institut ... Medicine (MDC) Berlin-Buch and Professor Gary Lewin (MDC), ... and Nijmegen, the Netherlands. The research findings, which ...
... , FRIDAY, Dec. 9 (HealthDay News) -- Premature infants ... than full-term babies, new research shows. However, the ... Candida fungus, are also more dangerous, researchers from Duke University ... [full-term] infants, whereas in premature infants, they seem to be ...
... were common and long-lasting during the first two ... a new study from Johns Hopkins University School ... factor for impaired physical function. "Early identification ... as a potential,intervention to improve long-term outcomes in ...
Cached Medicine News:Health News:Model shows how façade pollutants make it into the environment 2Health News:Broadway Strikes an Autism-Friendly Chord 2Health News:Broadway Strikes an Autism-Friendly Chord 3Health News:Broadway Strikes an Autism-Friendly Chord 4Health News:Clemson University opens bioengineering research lab at Greenville hospital campus 2Health News:Clemson University opens bioengineering research lab at Greenville hospital campus 3Health News:People with DFNA2 hearing loss show increased touch sensitivity 2Health News:People with DFNA2 hearing loss show increased touch sensitivity 3Health News:Preemies Infected With More Dangerous Types of Bacteria: Study 2Health News:Depressive symptoms and impaired physical function are frequent and long-lasting after ALI 2
Inquire...
Inquire...
Inquire...
One Piece: Premier Pouches - Premier pouches provide the ultimate in skin protection with our long wearing Flextend skin barriers and superior comfort with our soft and silky ComfortWear panels....
Medicine Products: